Virtual Exhibit: 
https://www.dsifp.com/event/ahn-sabcs-review-1-28-2022/
 


Mario Tenore / Oncology Territory Manager, Rare Disease / mtenore@dsi.com / 732-232-1440


Lea Kleespies / Senior Oncology Territory Manager, Supportive Care / lkleespies@dsi.com / 724-552-6358

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Virtual Exhibit Hall Home

 

 

 

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Co., Ltd., is headquartered in Basking Ridge, New Jersey, and is focused on the development of oncology and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for metastatic breast cancer, gastric cancer,  tenosynovial giant cell tumor, hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, and IV iron therapy.

 

Product Website: www.her2mbctreatmenthcp.com

Company Website: www.daiichisankyo.us